RCUS Stock Down on Decision to Discontinue GILD Partnered Study

Key Takeaways RCUS fell 14.4% after discontinuing the phase III STAR-221 study in upper GI cancers following OS data.The domvanalimab combo failed to beat nivolumab plus chemo on survival, though safety was comparable.RCUS will pivot focus to casdatifan and other oncology and I&I programs, with cash funding into 2028.Shares of Arcus Biosciences, Inc. (RCUS) , a clinical-stage biopharmaceutical company, declined 14.4% following the announcement that its late-stage STAR-221 study was discontinued for futility ...